IGF-1 LR3 is a modified form of Insulin-like Growth Factor-1 with 3x higher potency and a 20–30x longer half-life than native IGF-1. For women, it provides a direct pathway to muscle preservation, body recomposition, and anti-aging that is independent of testosterone levels.
IGF-1 LR3 binds IGF-1 receptors in muscle, bone, and connective tissue with 3x higher potency than native IGF-1 and a 20–30x longer half-life (20–30 hours vs 15–20 minutes). This extended receptor activation drives protein synthesis, satellite cell activation, and anti-apoptotic signaling in muscle tissue.
Unlike testosterone, which primarily drives muscle hypertrophy (larger existing fibers), IGF-1 LR3 promotes both hypertrophy and hyperplasia (new muscle fiber formation via satellite cell activation). For women, who have lower androgen levels, IGF-1 LR3's hyperplasia mechanism provides a unique pathway to lean mass gain that is not dependent on testosterone.
The LR3 modification (Arg3 substitution) reduces IGF-1 LR3's affinity for IGF-binding proteins (IGFBPs) by ~500-fold compared to native IGF-1. This means more free IGF-1 LR3 is available to activate receptors, making it significantly more bioavailable than endogenous IGF-1 at equivalent doses.
Women should start at the lower end (20 mcg/day) and always inject with food to mitigate hypoglycemia risk. Cycling is mandatory — 4 weeks on, 4 weeks off.
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Weeks 1–2 (Low dose) | 20 mcg/day | Once daily SubQ, post-workout | Start low to assess hypoglycemia sensitivity. Inject with a meal or carbohydrate source. |
| Weeks 3–4 (Standard) | 30–50 mcg/day | Once daily SubQ, post-workout | Increase if tolerating well. 50 mcg is the upper end for most women. |
| Weeks 5–6 (Cycle end) | 20–30 mcg/day | Once daily SubQ | Taper down in final 2 weeks to minimize receptor desensitization. |
| Off period (Weeks 7–10) | Off IGF-1 LR3 | Use CJC-1295 + Ipamorelin | Maintain GH pulsatility during off weeks. IGF-1 receptor sensitivity restores. |
| Benefit | Evidence Level | Mechanism | Timeframe |
|---|---|---|---|
| Muscle preservation (caloric deficit) | Strong (IGF-1 data) | Protein synthesis, anti-catabolism | 2–4 weeks |
| Lean mass gain | Strong | Satellite cell activation, hyperplasia | 4–8 weeks |
| Fat loss (body recomposition) | Moderate | Lipolysis, insulin sensitivity | 6–12 weeks |
| Skin & collagen quality | Moderate (indirect) | Fibroblast activation, collagen synthesis | 8–16 weeks |
| Bone density | Moderate (IGF-1 data) | Osteoblast activation | 6–12 months |
≥99% purity, third-party COA verified. Use code HEALTH for 15% off.
Shop IGF-1 LR3 at Purgo LabsIGF-1 LR3 (Insulin-like Growth Factor-1 Long Arg3) is researched in women for muscle preservation during caloric restriction, body recomposition, anti-aging (skin, collagen, bone density), and metabolic health. Women over 35 experiencing age-related muscle loss (sarcopenia) and declining IGF-1 levels may particularly benefit. It is also used in athletic contexts for recovery and lean mass maintenance.
Research protocols for women typically use 20–50 mcg per day, lower than the 50–100 mcg range used in men due to body weight and hormonal differences. IGF-1 LR3 is administered subcutaneously, typically post-workout or in the morning. Cycle length is 4–6 weeks, followed by a 4-week off period to prevent IGF-1 receptor desensitization.
IGF-1 LR3 does not directly affect estrogen or progesterone. However, elevated IGF-1 may modestly influence estrogen metabolism and insulin sensitivity. Women with PCOS (who already have elevated IGF-1 and insulin resistance) should use caution — IGF-1 LR3 may exacerbate insulin resistance in this population. Women on estrogen HRT may experience enhanced IGF-1 effects due to estrogen's synergistic role in GH/IGF-1 signaling.
Yes — IGF-1 decline is a primary driver of age-related changes in women: reduced muscle mass, increased visceral fat, declining skin collagen, and decreased bone density. IGF-1 LR3 restores IGF-1 signaling in peripheral tissues, supporting lean mass maintenance, skin quality, and bone health. The anti-aging application typically uses lower doses (20–30 mcg/day) on a 4-weeks-on/4-weeks-off cycle.
IGF-1 LR3 has a more complex safety profile than BPC-157 or TB-500. At research doses (20–50 mcg/day), the most common side effects are hypoglycemia (low blood sugar), water retention, and mild joint discomfort. Women should inject post-meal or with a carbohydrate source to mitigate hypoglycemia risk. IGF-1 LR3 should not be used by women with a history of hormone-sensitive cancers, as IGF-1 promotes cell proliferation.
CJC-1295 stimulates endogenous GH release, which then drives IGF-1 production — a more physiological approach with a lower side effect profile. IGF-1 LR3 directly activates IGF-1 receptors in peripheral tissues, bypassing the GH axis for a more potent but less selective effect. For most women, CJC-1295 + Ipamorelin is the preferred starting point; IGF-1 LR3 is reserved for women who have plateaued on GHRH/GHRP protocols or need more targeted muscle preservation.
Yes — cycling is essential with IGF-1 LR3. Continuous use leads to IGF-1 receptor downregulation and diminishing returns. The standard protocol is 4 weeks on, 4 weeks off. During the off period, IGF-1 receptor sensitivity is restored. Women can use CJC-1295 + Ipamorelin during the off weeks to maintain GH pulsatility without direct IGF-1 receptor stimulation.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.